Universal Beteiligungs und Servicegesellschaft mbH Sells 135,470 Shares of Bruker Corporation $BRKR

Key Points

• Universal Beteiligungs cut its stake in Bruker by 23.6%, selling 135,470 shares in Q4 and now holds 437,694 shares (~0.29% of the company) valued at $20.79 million.
• Bruker missed quarterly EPS ($0.59 vs. $0.65 expected) but beat revenue ($977.2M vs. $964.6M) and issued FY2026 guidance of $2.10–$2.15 EPS (analysts' consensus ~2.12).
• Analyst sentiment is mixed with an average rating of Hold and an average price target of $49.38, while several firms recently lowered targets; the stock trades in a one‑year range of $28.53–$56.22 (market cap ≈ $5.57B).

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in Bruker Corporation (NASDAQ:BRKR - Free Report) by 23.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 437,694 shares of the medical research company's stock after selling 135,470 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.29% of Bruker worth $20,790,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Allworth Financial LP lifted its holdings in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Linden Thomas Advisory Services LLC increased its position in shares of Bruker by 2.1% during the third quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company's stock valued at $639,000 after acquiring an additional 396 shares during the last quarter. Arizona State Retirement System increased its position in shares of Bruker by 1.4% during the third quarter. Arizona State Retirement System now owns 31,369 shares of the medical research company's stock valued at $1,019,000 after acquiring an additional 435 shares during the last quarter. Meixler Investment Management Ltd. increased its position in shares of Bruker by 4.3% during the third quarter. Meixler Investment Management Ltd. now owns 12,983 shares of the medical research company's stock valued at $422,000 after acquiring an additional 530 shares during the last quarter. Finally, CWM LLC increased its position in shares of Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company's stock valued at $77,000 after acquiring an additional 542 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Stock Performance

NASDAQ:BRKR opened at $36.60 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The business has a fifty day simple moving average of $37.32 and a two-hundred day simple moving average of $41.87. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $56.22. The company has a market capitalization of $5.57 billion, a P/E ratio of -243.99, a P/E/G ratio of 2.17 and a beta of 1.20.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The firm had revenue of $977.20 million during the quarter, compared to analysts' expectations of $964.61 million. During the same period in the prior year, the business earned $0.76 earnings per share. The business's quarterly revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Monday, March 23rd. Bruker's dividend payout ratio (DPR) is currently -133.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company's stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 27.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Bruker in a research report on Friday, March 27th. Guggenheim decreased their price target on Bruker from $58.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Jefferies Financial Group set a $50.00 price target on Bruker in a research report on Thursday, February 12th. Citigroup decreased their price target on Bruker from $53.00 to $40.00 and set a "neutral" rating for the company in a research report on Friday, February 13th. Finally, The Goldman Sachs Group decreased their price target on Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $49.38.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.